FSDDF - FSD Pharma Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
9.09
0.00 (0.00%)
As of 3:58PM EST. Market open.
Stock chart is not supported by your current browser
Previous Close9.09
Open11.37
Bid0.00 x 0
Ask0.00 x 0
Day's Range9.09 - 9.09
52 Week Range3.93 - 56.88
Volume18,300
Avg. Volume7,366
Market Cap72.258M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.00
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Seasoned Healthcare Executive and Academic Luminary Larry Kaiser, MD, Joins FSD Pharma Board of Directors
    CNW Group

    Seasoned Healthcare Executive and Academic Luminary Larry Kaiser, MD, Joins FSD Pharma Board of Directors

    TORONTO , Jan. 22, 2020 /CNW/ - FSD Pharma Inc. (HUGE) (HUGE.CN) (FRA: 0K9A) ("FSD Pharma" or the "Company") today announced that it has appointed Larry Kaiser , MD, FACS to its Board of Directors, effective immediately. Dr. Kaiser will also continue to serve as the Chairman of FSD Pharma's Scientific Advisory Board (SAB). Dr. Kaiser is currently the Managing Director with the Healthcare Industry Group at Alvarez and Marsal, a leading global professional services firm.

  • CNW Group

    FSD Pharma to Ring Nasdaq Opening Bell on Wednesday, January 22, 2020

    TORONTO , Jan. 17, 2020 /CNW/ - FSD Pharma Inc. (HUGE.CN) (HUGE.CN) (FRA: 0K9) ("FSD Pharma" or the "Company") is pleased to announce that Executive Co-Chairman and CEO Dr. Raza Bokhari , along with the founders, members of the Company's Board of Directors, members of the leadership team, early investors, advisors, and other stakeholders, will ring the Nasdaq Stock Market opening bell on Wednesday, January 22, 2020, at 9:30 am ET. The Opening Bell Ringing Ceremony will be held at Nasdaq's MarketSite in New York City and will be webcast live beginning at 9:20 am ET via the following link: https://www.nasdaq.com/marketsite/bell-ringing-ceremony and live streaming will be available on Facebook at the following link: http://Facebook.com/Nasdaq. "It will indeed be a unique privilege for me to ring the opening bell at Nasdaq to commence trading in the presence of FSD Pharma's extended family and friends," said Raza Bokhari , MD, Executive Co-Chairman and CEO.

  • InvestmentPitch Media Video Discusses FSD Pharma's New Listing on the  Nasdaq Capital Market and Upcoming Biotech and Healthcare Conferences - Video Available on Investmentpitch.com
    Newsfile

    InvestmentPitch Media Video Discusses FSD Pharma's New Listing on the Nasdaq Capital Market and Upcoming Biotech and Healthcare Conferences - Video Available on Investmentpitch.com

    Vancouver, British Columbia--(Newsfile Corp. - January 10, 2020) - FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FSE: 0K9), a specialty, biotech pharmaceutical R&D company, has started trading on the Nasdaq Capital Market under the symbol "HUGE". FSD Pharma is focused on developing, over time, a robust pipeline of FDA approved synthetic compounds targeting the endocannabinoid system of the human body to treat certain diseases of the central nervous system and autoimmune disorders of ...

  • Business Wire

    INSERTING and REPLACING FSD Pharma to Commence Trading on Nasdaq Capital Market Under Symbol ‘HUGE’

    Insert in second paragraph, first sentence of release: Executive Co-Chairman and CEO.

  • FSD Pharma to Commence Trading on Nasdaq Capital Market Under Symbol 'HUGE'
    CNW Group

    FSD Pharma to Commence Trading on Nasdaq Capital Market Under Symbol 'HUGE'

    FSD Pharma to Commence Trading on Nasdaq Capital Market Under Symbol 'HUGE'

  • Benzinga

    FSD Pharma To Start Trading On Nasdaq This Week

    FSD Pharma Inc (CSE: HUGE) (OTC: FSDDF )   said Monday that its Class B Subordinate Voting Shares have been accepted for listing on the NASDAQ Capital Market under the ticker "HUGE." The stock ...

  • Business Wire

    FSD Pharma to Begin Trading on the NASDAQ Capital Market Under Symbol ‘HUGE’ on January 9, 2020

    FSD Pharma Inc. (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) ("FSD Pharma" or the "Company") today announced that its Class B Subordinate Voting Shares (the "Shares") have been approved for listing on the NASDAQ Capital Market ("NASDAQ") under the symbol ‘HUGE’. Trading on the NASDAQ is expected to commence at market open on Thursday, January 9, 2020.

  • FSD Pharma to Begin Trading on the NASDAQ Capital Market Under Symbol 'HUGE' on January 9, 2020
    CNW Group

    FSD Pharma to Begin Trading on the NASDAQ Capital Market Under Symbol 'HUGE' on January 9, 2020

    Trading on the NASDAQ is expected to commence at market open on Thursday, January 9, 2020 . The Company's Shares will continue to be listed on the Canadian Securities Exchange under the symbol 'HUGE'.

  • Business Wire

    FSD Pharma Strengthens Management Team

    FSD Pharma Inc. (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) ("FSD Pharma" or the "Company") today announced the appointments of three key executives: Donal Carroll, Chief Financial Officer. Mr. Carroll previously served as interim CFO; Sandra Lottes, Pharm D, Vice President & Head of Clinical Research of FSD Pharma’s BioSciences Division; and Shahzad Shah, Chief Operating Officer of FV Pharma.

  • InvestmentPitch Media Video Discusses FSD Pharma's Approval of Listing Application for Nasdaq Capital Market with trading Anticipated to Begin Shortly - Video Available on Investmentpitch.com
    Newsfile

    InvestmentPitch Media Video Discusses FSD Pharma's Approval of Listing Application for Nasdaq Capital Market with trading Anticipated to Begin Shortly - Video Available on Investmentpitch.com

    Vancouver, British Columbia--(Newsfile Corp. - December 17, 2019) - FSD Pharma Inc. (CSE: HUGE) (FSE: 0K9) (OTCQB: FSDDF), a specialty, biotech pharmaceutical R&D company, reports its application to list its Class B Subordinate Voting Shares on the Nasdaq Capital Market has been approved by Nasdaq and the company anticipates trading on Nasdaq to begin shortly. FSD Pharma is focused on developing a robust pipeline of FDA approved synthetic compounds targeting the endocannabinoid system of ...

  • Benzinga

    FSD Pharma To List On Nasdaq Capital Market

    FSD Pharma Inc. (CSE: HUGE) (OTC: FSDDF ) said Monday it has obtained approval for its Class B subordinate shares to list on the Nasdaq Capital Market. The company hasn’t provided a specific date for when ...

  • FSD Pharma Receives Approval to List its Shares on Nasdaq
    CNW Group

    FSD Pharma Receives Approval to List its Shares on Nasdaq

    FSD Pharma Receives Approval to List its Shares on Nasdaq

  • Business Wire

    FSD Pharma Receives Approval to List Its Shares on Nasdaq

    FSD Pharma Inc. (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) ("FSD Pharma" or the "Company") announces that Nasdaq has approved its application to have its Class B Subordinate Voting Shares (the "Shares") listed on the Nasdaq Capital Market ("Nasdaq"). FSD Pharma expects the Shares to commence trading on Nasdaq in the near future.

  • FSD Pharma to Present at Investor Summit on December 17
    CNW Group

    FSD Pharma to Present at Investor Summit on December 17

    Mr. Bokhari will be available during the day on December 17 for one-on-one meetings. Mr. Bokhari's presentation will be webcast live and available for replay on the 'Events and Presentations' section of the 'Investors' page of the FSD Pharma website, www.fsdpharma.com, or via https://www.webcaster4.com/Webcast/Page/2038/32606.

  • Business Wire

    FSD Pharma to Present at 12th Annual LD Micro Main Event Investor Conference on December 11

    FSD Pharma Inc. (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) ("FSD Pharma" or the "Company") announces that Edward Brennan, MD, President, BioSciences Division, will present an overview of the Company at the 12th Annual LD Micro Main Event Investor conference at 12:20 p.m. PT/3:20 p.m. ET on Wednesday, December 11, 2019 at the Luxe Sunset Boulevard Hotel in Los Angeles. The conference will be held December 10-12, 2019. Dr. Brennan will also host one-on-one meetings with investors throughout the day.

  • Benzinga

    Cannabis Earnings Roundup: 4Front, WeedMD, FSD Pharma, 1933 Industries, True Leaf

    As cannabis earnings season continues, Benzinga took a look at the quarterly prints from four companies in the sector Monday.  4Front Ventures Reports $6.86M Quarterly Net Loss 4Front Ventures Corp. (CSE: ...

  • Business Wire

    FSD Pharma Reports Third Quarter 2019 Financial Results

    These financial results are unaudited, are prepared in accordance with International Financial Reporting Standards (IFRS) and are reported in Canadian dollars. The Company intends to initiate Phase 1 first-in-human safety and tolerability trials for its lead candidate, PP 101 micro-PEA during 1Q20.

  • FSD Pharma Second Tranche of Private Placement Closes, Total of $4.59 Million Raised at $20.10 To Date, Extends Offering
    CNW Group

    FSD Pharma Second Tranche of Private Placement Closes, Total of $4.59 Million Raised at $20.10 To Date, Extends Offering

    TORONTO , Nov. 4, 2019 /CNW/ - FSD Pharma Inc. (HUGE.CN) (OTCQB:FSDDD) (0K9.F) ("FSD" or the "Company") announces that it has closed a second tranche of its previously announced private placement (the "Private Placement"), and has now raised total gross proceeds of CAD $4,596,285 from investors, including members of senior management and the Board of Directors, issuing an aggregate of 228,671 class B subordinate voting shares (the "Shares"). The Shares issued to purchasers in Canada will be subject to a four-month hold period, in accordance with applicable Canadian securities laws. The Company expected to close the Private Placement by October 31, 2019 , however, it has elected to extend the Private Placement to accommodate potential additional interest from institutional grade investors.

  • FSD Pharma Announces the Filing of an Amended Annual MD&A for 2018
    CNW Group

    FSD Pharma Announces the Filing of an Amended Annual MD&A for 2018

    TORONTO , Oct. 23, 2019 /CNW/ - FSD Pharma Inc. (HUGE.CN) (FSDDF) (0K9.F) ("FSD" or the "Company") announces that an amended and restated management's discussion and analysis for the year ended December 31, 2018 (the "Amended 2018 MD&A") has been filed on SEDAR to better comply with National Instrument 51-102 – Continuous Disclosure Obligations. The Amended 2018 MD&A was prepared following a continuous disclosure review by the Ontario Securities Commission ("OSC") of the Company's disclosure record. The Amended 2018 MD&A was filed to address comments received from OSC staff and in order to improve the Company's disclosure.

  • Newsfile

    InvestmentPitch Media Video Discusses FSD Pharma's New OTCQB Symbol and Appointment of Former U.S. Congressman Stephen Buyer to its Board of Directors - Video Available on Investmentpitch.com

    Vancouver, British Columbia--(Newsfile Corp. - October 18, 2019) - FSD Pharma Inc. (CSE: HUGE) (FSE: 0K9) (OTCQB: FSDDD) announced that its Class B shares, which trade on the OTCQB, will have a new symbol FSDDD for a period of 20 business days until November 13th, at which time the symbol will revert back to FSDDF. The temporary change is protocol for stocks that trade on US exchanges that undergo structural events, such as ...